Our finding that Elovl6 loss hampers AML propagation will facilitate the development of novel cancer treatments; ELOVL6 activity or pathways regulated by ELOVL6 are potential targets of anti-AML therapy. The gene discussed is ELOVL6; the disease is cancer.